Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
BIORA THERAPEUTICS, INC. (PROG) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/11/2023 8-K Quarterly results
10/06/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/14/2023 8-K Investor presentation, Quarterly results
Docs: "Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results NaviCapTM targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device BioJetTM systemic oral delivery platform device development achieved function targets while continuing to exceed bioavailability targets The company strengthened its intellectual property position with additional patents for both platforms Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific",
"THERAPEUTIC PIPELINE PROGRAM PROGRAM INDICATION DESIGN/FEASIBILITY PRECLINICAL CLINICAL TARGETED THERAPEUTICS"
06/08/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/20/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023"
01/09/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Elimination of Series X Preferred Stock",
"Certificate of Elimination of Series X Preferred Stock"
12/30/2022 8-K Quarterly results
12/19/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/10/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
11/09/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/27/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Company, effective April 26, 2022",
"Second Amended & Restated Bylaws of Biora Therapeutics, Inc"
03/28/2022 8-K Investor presentation, Quarterly results
Docs: "Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company’s Targeted Therapeutics Clinical Programs with Initiation of Clinical Device Performance Study in Patients with Ulcerative Colitis Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific",
"TARGETED THERAPEUTICS SYSTEMIC THERAPEUTICS PGN-001"
02/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/20/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...
Docs: "Progenity Unaudited Pro Forma Condensed Consolidated Financial Information SAN DIEGO, December 20, 2021 – Progenity, Inc. , a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, closed the divestiture of its affiliate Avero Diagnostics through an asset sale to Northwest Pathology. Beginning in the second quarter of 2021, Avero’s historical financial results for periods prior to the divestiture will be reflected in Progenity’s condensed consolidated financial statements as discontinued operations. The following unaudited pro forma condensed consolidated statement of income of Progenity for the year ended December 31, 2020 is presented as if the divestiture had occurred as of January 1, 2020 and gives effect to the elimination of the ..."
11/22/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"At Market Issuance Sales Agreement, by and among Progenity, Inc., B. Riley Securities, Inc., BTIG, LLC, and H.C. Wainwright & Co. LLC",
"Opinion of Gibson, Dunn & Crutcher LLP"
11/10/2021 8-K Investor presentation, Quarterly results
Docs: "Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results Added important patents further protecting the company’s therapeutic delivery technologies Added strong biotherapeutics capabilities to management team and board of directors Implemented cost-cutting measures expected to result in approximately $145 million in cost savings on an annual basis1 Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific",
"ORAL DELIVERY OF BIOTHERAPEUTICS GI-TARGETED THERAPEUTICS ODBS"
11/09/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment",
"PROGENITY, INC. 2021 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS ON NOVEMBER 3, 2021 1. GENERAL. Eligible Award Recipients. New Employees are eligible to receive Awards as a material inducement to the commencement of employment within the meaning of the Listing Rule. Available Awards. The Plan provides for the grant of the following Awards: Nonstatutory Stock Options; Stock Appreciation Rights; Restricted Stock Awards; Restricted Stock Unit Awards; Performance Stock Awards; and Other Stock Awards. Purpose. The Plan, through the granting of Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the elig...",
"Progenity Appoints Adi Mohanty as Chief Executive Officer"
11/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Progenity Announces Appointment of Jill Howe to its Board of Directors SAN DIEGO - November 4, 2021 - Progenity, Inc . , an innovative biotechnology company, announced the appointment of Jill Howe to its board of directors effective November 3, 2021. Ms. Howe was also appointed chairperson of the Audit Committee and member of the Nominating and Corporate Governance Committee. “As Progenity continues to execute its strategic transformation, we are adding key leadership capabilities that will allow us to continue accelerating our efforts to develop the drug discovery and delivery systems of the future,” said Eric d'Esparbes, interim CEO of Progenity. “Jill brings proven financial leadership and extensive pharmaceutical industry experience, which will be invaluable in her role as chair of the..."
10/27/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Gibson, Dunn & Crutcher LLP",
"Opinion of Gibson, Dunn & Crutcher LLP"
10/26/2021 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"PROGENITY REDUCES OUTSTANDING DEBT BY $20.175 MILLION THROUGH A PRIVATE EXCHANGE OF $20.175 MILLION OF ITS 7.25% CONVERTIBLE SENIOR NOTES DUE 2025 FOR SHARES OF COMMON STOCK"
10/06/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Gibson, Dunn & Crutcher LLP",
"Form of Securities Purchase Agreement, by and between the Company and the Purchasers signatory therein"
09/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement and General Release, by and between the registrant and Harry Stylli, Ph.D",
"Separation Agreement and General Release, by and between the registrant and Harry Stylli, Ph.D"
08/23/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Form of Warrant",
"Opinion of Gibson, Dunn & Crutcher LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy